You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Remove Complementary medicines filter Complementary medicines (7)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Remove Prescription medicines filter Prescription medicines (7)
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Complementary medicines filter Complementary medicines
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Prescription medicines filter Prescription medicines
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Building a more robust medicine supply - proposals to help prevent, mitigate and manage medicine shortages
Closed on 17 May 2021
Repurposing of prescription medicines
Closed on 30 March 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
Consultations on adoption of European Union guidelines in Australia
Closed on 7 February 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Boxed Warning guidance
Closed on 31 August 2018
Prescription strong (Schedule 8) opioid use and misuse in Australia – options for a regulatory response
Closed on 2 March 2018
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018